Christopher Peetz
Founder bij MIRUM PHARMACEUTICALS, INC.
Vermogen: 8 M $ op 31-03-2024
Profiel
Christopher Peetz is the founder of Mirum Pharmaceuticals, Inc. (founded in 2018) where he holds the title of Chief Executive Officer & Director.
He is currently the Chief Executive Officer at Satiogen Pharmaceuticals, Inc. and an Independent Director at Alpine Immune Sciences, Inc. Mr. Peetz's former positions include being the Chief Executive Officer at Flashlight Therapeutics, Inc. from 2014 to 2016, Senior Director-Corporate Development & Strategy at Onyx Pharmaceuticals, Inc. from 2007 to 2012, and Vice President-Finance & Development at SillaJen Biotherapeutics, Inc. from 2012 to 2014.
He also held the position of Chief Financial Officer & Head-Development at Tobira Therapeutics, Inc. from 2014 to 2016.
Mr. Peetz received his undergraduate degree from Washington University in St. Louis and an MBA from Stanford Graduate School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 02-02-2024 | 305 682 ( 0.66% ) | 8 M $ | 31-03-2024 | |
| 02-01-2024 | 1 900 ( 0.00% ) | 75 316 $ | 31-03-2024 |
Actieve functies van Christopher Peetz
| Bedrijven | Functie | Begin |
|---|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Director/Board Member | 24-04-2018 |
| MIRUM PHARMACEUTICALS, INC. | Founder | 07-05-2018 |
Satiogen Pharmaceuticals, Inc.
 Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Chief Executive Officer | - |
Eerdere bekende functies van Christopher Peetz
| Bedrijven | Functie | Einde |
|---|---|---|
Tobira Therapeutics, Inc. /Old/
 Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01-12-2016 |
| TOBIRA THERAPEUTICS INC | Director of Finance/CFO | 01-12-2016 |
Flashlight Therapeutics, Inc.
 Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Chief Executive Officer | 01-12-2019 |
SillaJen Biotherapeutics, Inc.
 SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01-03-2014 |
Onyx Pharmaceuticals, Inc.
 Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Corporate Officer/Principal | 01-01-2012 |
Opleiding van Christopher Peetz
| Washington University in St. Louis | Undergraduate Degree |
| Stanford Graduate School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| MIRUM PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 7 |
|---|---|
Onyx Pharmaceuticals, Inc.
Onyx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Onyx Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in developing innovative therapies that target the molecular mechanisms that cause cancer. The company was founded by Frank McCormick in February 1992 and is headquartered in Thousand Oaks, CA. | Health Technology |
TerraVia Holdings, Inc.
 TerraVia Holdings, Inc. Household/Personal CareConsumer Non-Durables TerraVia Holdings, Inc. engaged in the production of food, nutrition, and specialty ingredients from algae. It produced oils, specialty fats, and powdered ingredients using its microalgae-based technology platform. The company was founded by Jonathan S. Wolfson and Harrison F. Dillon on March 31, 2003 and was headquartered in San Francisco, CA. | Consumer Non-Durables |
SillaJen Biotherapeutics, Inc.
SillaJen Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services SillaJen Biotherapeutics, Inc. develops and commercializes cancer therapeutics. It focuses on the development and commercialization of first-in-class, breakthrough targeted oncolytic immunotherapy products for solid tumors. It is focused on two main programs, lead product candidate, which is in mid-stage clinical development for the treatment of advanced primary liver cancer and colorectal cancer and JX-929 which is under investigation for a variety of other solid tumors. The company was founded by John C. Bell and David H. Kirn in 2006 and is headquartered in San Francisco, CA. | Commercial Services |
Tobira Therapeutics, Inc. /Old/
Tobira Therapeutics, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, which focuses on developing and commercializing of therapies to treat liver disease, HIV, fibrosis and inflammation. Its lead product candidate, cenicriviroc or CVC, is a proprietary immunomodulator that may be used to treat a number of diseases, including NASH, kidney fibrosis, HIV-1 and others. The company was founded by Eckard Weber in September 2006 and is headquartered in South San Francisco, CA. | Health Technology |
Satiogen Pharmaceuticals, Inc.
Satiogen Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Satiogen Pharmaceuticals, Inc. engages in the development of therapeutic treatments for diabetes and obesity. It offers a metabolic mechanism for treating diabetes and obesity without intervention by systemically absorbed pharmaceuticals or invasive surgical methods. The firm’s product strategies include non-absorbed ASBT inhibitor, non-surgical biliary shunt, rectal satiogen, non-absorbed TGR5 ligand and labile bile acid sequestrant. The company was founded by Andrew Young and Bronislava Gedulin in 2007 and is headquartered in Del Mar, CA. | Commercial Services |
Tobira Therapeutics, Inc.
 Tobira Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tobira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The company was founded on October 6, 2006 and is headquartered in Madison, NJ. | Health Technology |
Flashlight Therapeutics, Inc.
Flashlight Therapeutics, Inc. BiotechnologyHealth Technology Flashlight Therapeutics, Inc. develops therapeutics for unmet medical needs. | Health Technology |
